A股異動丨艾比森一字漲停創近五個月新高 預計全年淨利潤同比增長132%至144%
格隆匯1月5日丨艾比森(300389.SZ)一字漲停,報12.58元,股價創近五個月新高,買一封單超21萬手,最新總市值40億元。艾比森昨晚公佈2021年度業績預吿,公司預計實現2021年歸屬於上市公司股東的淨利潤為2300萬元-3100萬元,同比增長132.3%-143.6%;預計基本每股收益為0.0733元/股-0.0989元/股。公司專注於LED顯示屏主業,產品涉及小間距屏、租賃屏、舞台創意屏、户外大屏、球場屏等,被廣泛應用於廣吿傳媒、地產、交通運輸、舞台演藝、廣播電視、體育場館、安防監控、指揮調度等領域。公司或將受益於2022冬奧會的到來。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.